Can Fite Biopharma (CANF) Leaps on FDA Nod

Can Fite Biopharma Ltd (NYSE MKT:

) shares vaulted 50% to $2.52 following announcement of the FDA Fast Track Designation for its CF102 in the treatment of liver cancer. Share volume totaled 4.6 million, swamping an all-day average of 5,500